Skip to main content
Tessa NewsLink
Paste a health news link, or browse

Source study found

Story checked

A blood-based approach could enable personalized immunotherapy without the need for a tumor biopsy (opens in a new tab)

medicalxpress.com · 2026-09-29

Short answerEvidenceSource

Short answer

Mostly not supported

Mostly not supported.

One claim goes further than the study. 4 other points were not covered by the paper.

  • 2 supported
  • 1 overstated
  • 4 not covered

Checked against the study summary. The full text wasn't available, so some details couldn't be settled either way.

Share this check

Follow the evidence trail
1
2

NewsLink checks it

Mostly not supported

One claim overstates the study. Two of seven check out. Four claims the study doesn't address.

  • 2 supported
  • 1 overstated
  • 4 not covered
Open claim evidence
3
Then inspect each claim

Evidence layer

Claim by claim

Each claim gets a verdict. Expand it to see the evidence directly below.

7 claims in this story

Showing all 7 claimsChoose a verdict to focus the list.

Claim 1 of 7OverstatedThe authors say the blood-based approach has the potential to replace or complement tissue-based neoantigen identification in many patients and cancer types, but they note that additional validation in larger patient cohorts is needed before it could be widely used in the clinic.View evidenceHide evidence

Why this verdict

The profile supports a speculative role for the approach as a surrogate or complement to tumor biopsy and reports that approximately half of a 69-patient cohort could be eligible. However, the story’s phrasing that it could replace or complement tissue-based neoantigen identification in many patients and cancer types pushes beyond the abstract profile, which explicitly leaves applicability across tumor types/stages and eligibility criteria unclear. The validation caveat is directionally consistent with the small proof-of-concept evidence.

1

Study evidence

A peripheral blood–only workflow (cfDNA WES + PD-1/CD39 T-cell sorting) recovered most neoantigens detected by standard tumor-biopsy–based methods in an initial cohort of eight metastatic cancer patients.

“We propose a novel strategy relying solely on peripheral blood to identify non-synonymous mutations via cell-free DNA whole-exome sequencing and isolate neoantigen-specific CD4+ and CD8+ T cells based on PD-1 and CD39 co-expression.”
2

Study evidence

Approximately half of 69 metastatic cancer patients were reported as eligible for the proposed blood-only neoantigen and reactive T-cell discovery approach.≈50%

“Analysis of a cohort of 69 metastatic cancer patients revealed that approximately half could be eligible for our blood-only approach.”
Claim 2 of 7Not coveredThe researchers isolated and sequenced ctDNA from blood samples of six patients with metastatic melanoma, breast cancer, head and neck cancer or colorectal cancer, and compared ctDNA-based neoantigen detection with conventional tumor tissue analysis in the same patients.View evidenceHide evidence

As statedsix patients

Why this verdict

The abstract-level profile supports an initial metastatic-cancer proof-of-concept cohort and a comparison with biopsy-based methods, but it describes n=8, not the story’s specific six-patient subset, cancer-type list, or the exact details of ctDNA isolation/sequencing in those same patients. Those details are not verifiable from the abstract profile.

1

Study evidence

A peripheral blood–only workflow (cfDNA WES + PD-1/CD39 T-cell sorting) recovered most neoantigens detected by standard tumor-biopsy–based methods in an initial cohort of eight metastatic cancer patients.

“We propose a novel strategy relying solely on peripheral blood to identify non-synonymous mutations via cell-free DNA whole-exome sequencing and isolate neoantigen-specific CD4+ and CD8+ T cells based on PD-1 and CD39 co-expression.”
Claim 3 of 7Not coveredAcross the six patients, ctDNA analysis identified 63.25% to 97.4% of the neoantigens identified by standard tumor tissue analysis.View evidenceHide evidence

As stated63.25% to 97.4%

Why this verdict

The profile says the blood-only workflow recovered 'most' biopsy-detected neoantigens, but the abstract-level evidence does not provide the stated 63.25% to 97.4% range. The quantitative range cannot be verified at this depth.

1

Study evidence

A peripheral blood–only workflow (cfDNA WES + PD-1/CD39 T-cell sorting) recovered most neoantigens detected by standard tumor-biopsy–based methods in an initial cohort of eight metastatic cancer patients.

“We propose a novel strategy relying solely on peripheral blood to identify non-synonymous mutations via cell-free DNA whole-exome sequencing and isolate neoantigen-specific CD4+ and CD8+ T cells based on PD-1 and CD39 co-expression.”
Claim 4 of 7Not coveredT cells isolated from blood samples of six of eight patients recognized and reacted to neoantigens identified by ctDNA, tumor tissue or both.View evidenceHide evidence

As statedsix of eight patients

Why this verdict

The profile supports isolation and testing of neoantigen-reactive T cells in the initial n=8 cohort and says the approach increased detected T-cell reactivities, but it does not report the story’s specific 'six of eight patients' result or the breakdown by ctDNA-derived, tissue-derived, or shared neoantigens.

1

Study evidence

A peripheral blood–only workflow (cfDNA WES + PD-1/CD39 T-cell sorting) recovered most neoantigens detected by standard tumor-biopsy–based methods in an initial cohort of eight metastatic cancer patients.

“We propose a novel strategy relying solely on peripheral blood to identify non-synonymous mutations via cell-free DNA whole-exome sequencing and isolate neoantigen-specific CD4+ and CD8+ T cells based on PD-1 and CD39 co-expression.”
Claim 5 of 7Not coveredIn a separate cohort of 69 patients with various metastatic solid tumors, ctDNA was detectable in 32 of 69 patients (46.4%), and among 17 patients with colorectal cancer it was detectable in 14 (82.4%).View evidenceHide evidence

As stated32 of 69 patients (46.4%); 14 of 17 patients (82.4%)

Why this verdict

The profile supports a separate cohort of 69 metastatic cancer patients and says approximately half could be eligible for the blood-only approach. It does not provide exact counts of ctDNA detectability, the 32/69 and 14/17 figures, or a colorectal-cancer subgroup result.

1

Study evidence

Approximately half of 69 metastatic cancer patients were reported as eligible for the proposed blood-only neoantigen and reactive T-cell discovery approach.≈50%

“Analysis of a cohort of 69 metastatic cancer patients revealed that approximately half could be eligible for our blood-only approach.”
Claim 6 of 7SupportedIn a study published in Cancer Discovery, cancer neoantigens and neoantigen-specific T cells were identified from patient blood samples by analyzing circulating tumor DNA (ctDNA) and immune cells.View evidenceHide evidence

Why this verdict

The abstract-level profile supports the central claim that the study proposed a peripheral blood-only workflow using cell-free DNA whole-exome sequencing to identify non-synonymous mutations/neoantigens and PD-1/CD39-based sorting to isolate neoantigen-reactive CD4+ and CD8+ T cells.

1

Study evidence

A peripheral blood–only workflow (cfDNA WES + PD-1/CD39 T-cell sorting) recovered most neoantigens detected by standard tumor-biopsy–based methods in an initial cohort of eight metastatic cancer patients.

“We propose a novel strategy relying solely on peripheral blood to identify non-synonymous mutations via cell-free DNA whole-exome sequencing and isolate neoantigen-specific CD4+ and CD8+ T cells based on PD-1 and CD39 co-expression.”
Claim 7 of 7SupportedCtDNA analysis also identified many neoantigens not found by standard tumor tissue analysis, suggesting a blood-based approach may provide a more representative view of neoantigens across different tumor lesions in metastatic disease.View evidenceHide evidence

Why this verdict

The profile supports that the blood-only workflow uncovered additional neoantigens missed by tumor biopsy analysis, and the paper framing notes biopsy may under-sample tumor heterogeneity. The story’s interpretation is hedged as a possible implication, though the abstract profile does not quantify how many additional neoantigens were found.

1

Study evidence

A peripheral blood–only workflow (cfDNA WES + PD-1/CD39 T-cell sorting) recovered most neoantigens detected by standard tumor-biopsy–based methods in an initial cohort of eight metastatic cancer patients.

“We propose a novel strategy relying solely on peripheral blood to identify non-synonymous mutations via cell-free DNA whole-exome sequencing and isolate neoantigen-specific CD4+ and CD8+ T cells based on PD-1 and CD39 co-expression.”
Then look for missing context

Context layer

What the story carried across

Nothing material from the study was dropped.

8 things the story did carry across
  • Primary proof-of-concept: a peripheral blood-only workflow using cfDNA WES for neoantigen discovery plus PD-1/CD39-based sorting to isolate neoantigen-reactive CD4+ and CD8+ T cells in metastatic cancer patients.
  • Initial cohort size in the abstract profile is eight metastatic cancer patients, with performance compared against standard tumor-biopsy-based techniques.
  • The blood-only workflow recovered most biopsy-detected neoantigens, but the abstract profile does not quantify the proportion.
  • The workflow increased detected neoantigen-reactive T-cell reactivities and uncovered additional neoantigens missed by tumor biopsy analysis.
  • Larger cohort analysis: 69 metastatic cancer patients were analyzed and approximately half were reported as eligible for the proposed blood-only approach.
  • Major limitation: the initial proof-of-concept cohort is small, limiting statistical power and generalizability.
  • Major limitation: sensitivity and limit of detection of cfDNA WES for low-frequency tumor mutations are not described in the abstract profile.
  • Major limitation: applicability across tumor types/stages and possible selection biases are not specified in the abstract profile.
Then read the study layer

Study layer

Study at a glance

Scan the study first. Expand only the parts you want to inspect.

Pieces of work

2

Evidence read

study summary

Lead result

human in vivo

1Lead resulthuman in vivoDemonstrate a blood-only workflow to discover cancer neoantigens (via cfDNA WES) and isolate neoantigen-reactive CD4+ and CD8+ T cells (via PD-1/CD39-based sorting), showing it recovers most biopsy-based neoantigens and detects additional T-cell reactivities in an initial metastatic cancer cohort.Observational proof-of-concept cohortExpand

In plain English

In an initial proof-of-concept cohort of eight metastatic cancer patients, the authors report a peripheral blood–only workflow that uses cell-free DNA whole-exome sequencing to identify non-synonymous mutations (neoantigens) and isolates neoantigen-specific CD4+ and CD8+ T cells by sorting for PD-1 and CD39 co-expression; the blood-only approach reportedly recovered most neoantigens found by biopsy-based methods and detected additional T-cell reactivities and neoantigens missed by tumor biopsy.

Key findings

  • A peripheral blood–only workflow (cfDNA WES + PD-1/CD39 T-cell sorting) recovered most neoantigens detected by standard tumor-biopsy–based methods in an initial cohort of eight metastatic cancer patients.
  • The blood-only approach increased the number of neoantigen-reactive T-cell reactivities detected compared with standard biopsy-based techniques in the initial cohort.
“We propose a novel strategy relying solely on peripheral blood to identify non-synonymous mutations via cell-free DNA whole-exome sequencing and isolate neoantigen-specific CD4+ and CD8+ T cells based on PD-1 and CD39 co-expression.”
What this piece can’t prove

4 further details could not be confirmed from the summary.

2human in vivoQuantify, in a larger metastatic cancer cohort, the proportion of patients who would be eligible for the proposed blood-only neoantigen/T-cell discovery approach (feasibility/eligibility estimate).cohort analysisExpand

In plain English

In an analysis of 69 metastatic cancer patients, the authors report that approximately half of patients would be eligible for a blood-only neoantigen and reactive T-cell discovery approach.

Key findings

  • Approximately half of 69 metastatic cancer patients were reported as eligible for the proposed blood-only neoantigen and reactive T-cell discovery approach.≈50%
“Analysis of a cohort of 69 metastatic cancer patients revealed that approximately half could be eligible for our blood-only approach.”
What this piece can’t prove
  • Abstract provides only a summary statement; key methodological details underlying the eligibility estimate are absent.
  • Unclear how eligibility was defined or operationalized across patients.

1 further detail could not be confirmed from the summary.

Finally, the search trail

Method layer

NewsLink found the paper. Tessa takes you deeper.

NewsLink checks the story. Tessa is where you inspect the paper, authors, evidence, and research context.

Open the paper in Tessa

Peripheral Blood as the Sole Source for Cancer Neoantigen and Reactive T-Cell Discovery

Cancer Discovery · 2026

Source record (opens in a new tab)

Why this one

Near certain

NewsLink found the paper. Tessa is where you inspect it deeply.

Papers considered

The selected paper, plus nearby candidates.

Crossref, PubMed, Europe PMC · 16 candidate papers

Selected

Peripheral Blood as the Sole Source for Cancer Neoantigen and Reactive T-Cell Discovery

Cancer Discovery · 2026 · Crossref

Source (opens in a new tab)
Candidate

Editor's evaluation: Decoupled neoantigen cross-presentation by dendritic cells limits anti-tumor immunity against tumors with heterogeneous neoantigen expression

2023 · Crossref

Source (opens in a new tab)
Candidate

PACM-09 NEOANTIGEN PREDICTION AND REACTIVITY OF CEREBROSPINAL FLUID-HUMAN DERIVED TUMOR REACTIVE T CELLS (CSF-TRT CELLS) IN LEPTOMENINGEAL DISEASE (LMD) FROM SOLID TUMORS

Neuro-Oncology Advances · 2026 · Crossref

Source (opens in a new tab)

And 10 more candidates considered.